Excelsior Biopharma (6496) — Cash Flow-to-Debt Ratio
Excelsior Biopharma (6496) has a Cash Flow-to-Debt Ratio of -0.03x as of December 2025, meaning its operating cash flow of NT$-22.21 Million could theoretically repay 0% of its total liabilities (NT$679.78 Million) in one year. See how much free cash does Excelsior Biopharma generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Excelsior Biopharma Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Excelsior Biopharma across 9 annual periods. Also explore 6496 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Excelsior Biopharma (2017–2025)
Year-by-year debt coverage analysis for Excelsior Biopharma. For market capitalisation and broader financial context, see 6496 market cap.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.20x | NT$-138.72 Million | NT$679.78 Million | ▼ -20.0% |
| 2024 | -0.17x | NT$-99.80 Million | NT$586.89 Million | ▲ +40.3% |
| 2023 | -0.28x | NT$-134.75 Million | NT$472.87 Million | ▼ -2736.3% |
| 2022 | 0.01x | NT$5.49 Million | NT$507.53 Million | ▼ -88.2% |
| 2021 | 0.09x | NT$55.82 Million | NT$608.90 Million | ▼ -89.1% |
| 2020 | 0.84x | NT$520.81 Million | NT$617.15 Million | ▲ +221.3% |
| 2019 | -0.70x | NT$-169.74 Million | NT$244.06 Million | ▼ -248.4% |
| 2018 | 0.47x | NT$126.92 Million | NT$270.88 Million | ▼ -54.5% |
| 2017 | 1.03x | NT$349.47 Million | NT$339.37 Million | — |